Larry Zeagler

The Memorandum of Understanding (MOU) recognizes the complementary nature of Alliance for Chemical Distribution (ACD) and American Chemistry Council (ACC), their respective performance programs, and their members’ critical roles in the chemical supply chain. Through the MOU, ACD and ACC pledge to work together to promote excellent performance, recruit unaffiliated organizations, and support public policy efforts to benefit the entire chemical industry. Learn more below.

23

Yuji's expertise lies not only in helping clients comply with evolving regulations but also in providing the R&D capabilities needed to address technical challenges. Read more about HFCs and the regulations associated with them below! #hfc #hfcphasedown #pfasalternatives #environmentallyfriendly #sustainable

1

Read the stunning second issue of our #ESOP Origin Story and see how #employeeownership is NMR Group, Inc.'s superpower https://lnkd.in/eumJTS3T

5

1 Comment

Essential reading for stakeholders in the #CommercialSterilization industry. Industry experts, Olivia Madamba of Thermo Fisher Scientific and Ethan Spira of AJW, Inc., answer pressing questions about the #EPA’s #EthyleneOxide #NESHAP final ruling and provide recommendations on #CEMS technology to support compliance and long-term resiliency. Read article. https://lnkd.in/genxbm_q #TFSCAD

12

1 Comment

Acceleration of downstream biologics process development through unique, PAT-driven understanding of unit ops. Learn how. 👉https://ow.ly/4ym550RMR3F

7

GMP certified CBG Isolate (Cannabigerol) is in stock at Laurelcrest. We are leaders in this cannabinoid and supply chain world wide. We are excited to continue learning about the power of this molecule. In a recently published a study in which 127 experienced CBG users were surveyed on their use of CBG-dominant products, including their use patterns, the perceived therapeutic effects of CBG, as well as its potential side effects12. Participants most frequently reported using CBG to manage anxiety (attested to by 51% of the sample), chronic pain (41%), depression (33%), and insomnia (31%). Moreover, most of the sample indicated that CBG was more effective than conventional medications for treating anxiety (78%), chronic pain (74%), depression (80%), and insomnia (73%) https://lnkd.in/gf9HbQDD #CBG #hemp #cannabigerol #science

13

1 Comment

Check out StratoChem Services' newest Publication! This month, Meagan A Wall dives into GC Peaks, discussing the basics. The view might not be as majestic from the tops of these peaks as one might prefer, but they're our bread and butter and pair perfectly with our interests and services. We look forward to your questions, feedback, and requests! What subjects would you like to learn more about? https://lnkd.in/gZJxmWCG

4

Chemical laboratories are hazard hotspots, requiring a strong commitment to safety protocols and training. This article examines the top 3 ways to foster a successful safety culture in chemical labs. https://lnkd.in/g5576q_c #chemicalsafety #ehs #labsafety #osha #highereducationleadership #Chemicallaboratories

11

Chemical laboratories are hazard hotspots, requiring a strong commitment to safety protocols and training. This article examines the top 3 ways to foster a successful safety culture in chemical labs. https://lnkd.in/g5576q_c #chemicalsafety #ehs #labsafety #osha #highereducationleadership #Chemicallaboratories

5

Chemical laboratories are hazard hotspots, requiring a strong commitment to safety protocols and training. This article examines the top 3 ways to foster a successful safety culture in chemical labs. https://lnkd.in/g5576q_c #chemicalsafety #ehs #labsafety #osha #highereducationleadership #Chemicallaboratories

3

Chemical laboratories are hazard hotspots, requiring a strong commitment to safety protocols and training. This article examines the top 3 ways to foster a successful safety culture in chemical labs. https://lnkd.in/g5576q_c #chemicalsafety #ehs #labsafety #osha #highereducationleadership #Chemicallaboratories

3

Chemical laboratories are hazard hotspots, requiring a strong commitment to safety protocols and training. This article examines the top 3 ways to foster a successful safety culture in chemical labs. https://lnkd.in/g5576q_c #chemicalsafety #ehs #labsafety #osha #highereducationleadership #Chemicallaboratories

1

Chemical laboratories are hazard hotspots, requiring a strong commitment to safety protocols and training. This article examines the top 3 ways to foster a successful safety culture in chemical labs. https://lnkd.in/g5576q_c #chemicalsafety #ehs #labsafety #osha #highereducationleadership #Chemicallaboratories

3

Claros Technologies, Inc. (“Claros”), Achieves Successful Commercial Pilot of its Disruptive High Throughput PFAS Destruction Technology   Claros is pleased to announce the completion of a successful pilot, demonstrating high-throughput destruction technology for per- and polyfluoroalkyl substances (PFAS) at a major chemical manufacturer/user’s commercial facility. The success of this pilot marks a significant milestone in Claros’ mission to commercialize effective treatment technologies for the elimination of PFAS waste and provides a ground-breaking and disruptive pathway for sustainability in fluoro-material manufacturing and use.  Key Highlights   High Throughput PFAS Destruction:  The Claros PFAS Destruction System achieved total (i.e. >99.99%) destruction performance on all target PFAS species (long, short and ultra-short chain PFAS) under high flow conditions in a commercial manufacturing setting. Claros’ next generation commercial PFAS Destruction system will exceed 45,000 gallons per day capacity using a single reactor unit by 1st quarter 2025. Stay tuned for more details: Going to WEFTEC? Visit us at Booth 1259 in the Innovation Pavillion.

46

5 Comments

Acceleration of downstream biologics process development through unique, PAT-driven understanding of unit ops. Learn how. 👉https://ow.ly/PoFZ50Sfg9E

4

Announced earlier in the year, Rahco's advanced #EPDM compound continues to serve as a reminder that custom rubber formulations matter. Here are three high-level elements to keep in mind -- https://lnkd.in/gz-7-6GU As far as the EPDM, resistant to hot water chloramines and compliant to ASTM D 6284-98, this polymer was developed for use of non-leaching materials in potable water. It adheres to NSF 61: Drinking Water System Components regulations with UL Certification. Rahco Rubber, Inc. | UL Solutions | ASTM International | NSF # . # . # . # . #RahcoToTheRescue #RubberIndustry #NSF #DrinkingWater #UL #WaterManagement #Chemistry #ManufacturIngIndustry #OEMs #Certification #Outsourcing #RubberProducts #QualityImprovement #NewProductDevelopment #ChemistryThatMatters #EngineeringSolutions #OEMFactory   #OEMSupplier #Manufacturing #NewProducts #EngineeringServices #ValueAddedServices #OEMParts #Purchasing #Supplier #SupplyChain

4

Neuren Pharmaceuticals has showcased noteworthy strategic progress and financial robustness over the past year. One of the pivotal achievements is the successful launch and robust market penetration of DAYBUE™ (trofinetide) in the U.S., recording net sales of US$177 million within nine months of its launch in 2023, with 2024 sales projections between US$370-420 million. This success is underpinned by Neuren's strategic partnership with Acadia Pharmaceuticals, which was further strengthened through a global licensing agreement, bringing in an upfront payment of US$100 million and promising future economic benefits tied to international sales. Neuren has also made significant strides in expanding its regulatory approval footprint. DAYBUE™ has gained priority review status from Health Canada and is progressing towards market entry in Europe and Japan. These efforts represent strategic moves to diversify and enhance global revenue streams. On the financial front, Neuren reported a profit after tax of A$157 million for 2023, driven by milestone and royalty revenues from Acadia. The company received a total of A$27 million in royalties, A$59 million in milestone payments, and an additional A$146 million from an expanded licensing agreement, reflecting a robust revenue stream with minimal direct costs, thus significantly boosting their net profit margins. Neuren's liquidity position remains strong, with cash and short-term investments totaling A$243.1 million as of 31 March 2024, up from A$228.5 million at the end of December 2023. This is indicative of their sound financial health and the ability to support further research and strategic initiatives. Further bolstering their market position, Neuren’s NNZ-2591 clinical program has shown promising Phase 2 results in treating several neurodevelopmental disorders, notably Phelan-McDermid and Pitt Hopkins syndromes. The company plans to announce Phase 2 results for Angelman syndrome in Q3 2024, positioning itself to address significant unmet medical needs Neuren's inclusion in the S&P/ASX 200 in September 2023 has enhanced its market visibility and attracted substantial institutional investment. Their active engagement in investor relations continues to fortify their market presence. In essence, Neuren Pharmaceuticals is on a definitive growth trajectory, characterized by strategic alliances, financial strength, and advanced clinical progress, positioning them well for sustained value creation and global market impact.

1